Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.54 |
| ▸ | CES1 | P23141 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 6/20 | 0.52 |
| ▸ | CA2 | P00918 | 6/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.50 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6223085 | 0.94 | ESR2 (0.54) | CES2CES1CA1CA2CA12 | |
| SCHEMBL6924446 | 0.87 | RAB9A (0.46) | SMN1; SMN2LMNAALDH1A1GAAHTT | |
| SCHEMBL5079945 | 0.83 | CES2 (0.47) | CES2CES1CA1CA2CA12 | |
| SCHEMBL8465124 | 0.82 | CES2 (0.50) | CES2CES1CA1CA2CA12 | |
| SCHEMBL652260 | 0.81 | LMNA (0.64) | SMN1; SMN2LMNACYP2C19CYP1A2CYP2C9 | |
| SCHEMBL7061292 | 0.80 | CES2 (0.58) | CES2CES1CA1CA2CA12 | |
| SCHEMBL1398350 | 0.80 | CES2 (0.58) | CES2CES1CA1CA2CA12 | |
| SCHEMBL6565732 | 0.80 | HSD17B10 (0.47) | SMN1; SMN2LMNACYP2C19CYP1A2CYP2C9 | |
| SCHEMBL6564201 | 0.80 | ELANE (0.52) | SMN1; SMN2LMNAHPGDPARP10PARP4 | |
| SCHEMBL2853759 | 0.79 | CES2 (0.55) | CES2CES1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 841 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635941-A1 | PROCESS FOR PREPARING A PEROXYESTER OR PEROXYCARBONATE | Nouryon Chemicals International B.V. (NL) | 2025-10-22 | — | — | EP | claimed |
| EP-4471010-B1 | PROCESS FOR PREPARING A PEROXYESTER OR PEROXYCARBONATE | NOURYON CHEMICALS INT BV (NL) | 2025-06-04 | — | — | EP | claimed |
| CN-119930651-A | Thiazolopiperidine-containing derivative, and preparation method and application thereof | 南开大学 | 2025-05-06 | — | — | CN | claimed |
| US-20240400490-A1 | PROCESS FOR PREPARING A PEROXYESTER OR PEROXYCARBONATE | NOURYON CHEMICALS INTERNATIONAL B.V. (NL) | 2024-12-05 | — | — | US | claimed |
| EP-4471010-A1 | PROCESS FOR PREPARING A PEROXYESTER OR PEROXYCARBONATE | Nouryon Chemicals International B.V. (NL) | 2024-12-04 | — | — | EP | claimed |
| CN-119059951-A | Process for preparing peroxyesters or peroxycarbonates | 诺力昂化学品国际有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-111592536-B | Monocyclic beta-lactam compound, preparation method and application thereof | 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） | 2023-11-03 | — | — | CN | claimed |
| CN-111592536-A | Monocyclic beta-lactam compound and preparation method and application thereof | 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） | 2020-08-28 | — | — | CN | claimed |
| EP-1595870-B1 | PROCESS FOR PRODUCING PHENYLALANINE DERIVATIVE HAVING QUINAZOLINEDIONE SKELETON AND INTERMEDIATE FOR THE SAME | AJINOMOTO KK (JP) | 2015-09-23 | — | — | EP | claimed |
| WO-2012140490-A2 | PROCESS FOR PREPARING QUINOLINE DERIVATIVE | AUROBINDO PHARMA LIMITED (IN) | 2012-10-18 | — | — | WO | claimed |
| US-8212035-B2 | Process for preparation of rosuvastatin calcium field of the invention | AUROBINDO PHARMA LTD. (IN) | 2012-07-03 | — | — | US | claimed |
| US-20090312547-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM FIELD OF THE INVENTION | AUROBINDO PHARMA LTD (IN) | 2009-12-17 | — | — | US | claimed |
| EP-2125754-A1 | AN IMPROVED PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM | Aurobindo Pharma Limited (IN) | 2009-12-02 | — | — | EP | claimed |
| WO-2008096257-A1 | AN IMPROVED PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LIMITED (IN) | 2008-08-14 | — | — | WO | claimed |
| EP-1315729-B1 | COMPOUNDS IN THE FORM OF HOMODIMERIC OR HETERODIMERIC PRODRUGS; PROCESS FOR OBTAINING THESE PRODRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASES-MEDIATED DISEASES OR DYSFUNCTION | CRISTALIA PROD QUIMICOS FARM (BR) | 2008-01-09 | — | — | EP | claimed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | claimed |
| WO-2006131828-A1 | A PROCESS FOR THE PREPARATION OF PERINDOPRIL | AUROBINDO PHARMA LIMITED (IN) | 2006-12-14 | — | — | WO | claimed |
| US-20050288343-A1 | Process of preparing substituted carbamates and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | claimed |
| WO-2005113521-A1 | PROCESS OF PREPARING SUBSTITUTED CARBAMATES AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-01 | — | — | WO | claimed |
| JP-6298926-A | — | — | None | — | — | JP | disclosed |
| EP-3788039-B1 | FACTOR XIIA INHIBITORS | UNIV LEEDS INNOVATIONS LTD (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| EP-4650348-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
| EP-4635941-A1 | PROCESS FOR PREPARING A PEROXYESTER OR PEROXYCARBONATE | Nouryon Chemicals International B.V. (NL) | 2025-10-22 | — | — | EP | disclosed |
| US-12448383-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250197410-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4471010-B1 | PROCESS FOR PREPARING A PEROXYESTER OR PEROXYCARBONATE | NOURYON CHEMICALS INT BV (NL) | 2025-06-04 | — | — | EP | disclosed |
| CN-119930651-A | Thiazolopiperidine-containing derivative, and preparation method and application thereof | 南开大学 | 2025-05-06 | — | — | CN | disclosed |
| CN-119591564-A | Long-acting prodrug derivative of vosulbactam, pharmaceutical composition and application thereof | 烟台药物研究所 | 2025-03-11 | — | — | CN | disclosed |
| US-12180217-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| CN-119161301-A | Nuciferine derivative prepared based on condensation reaction and preparation method and application thereof | 山东省农业科学院 | 2024-12-20 | — | — | CN | disclosed |
| US-20240400490-A1 | PROCESS FOR PREPARING A PEROXYESTER OR PEROXYCARBONATE | NOURYON CHEMICALS INTERNATIONAL B.V. (NL) | 2024-12-05 | — | — | US | disclosed |
| EP-4471010-A1 | PROCESS FOR PREPARING A PEROXYESTER OR PEROXYCARBONATE | Nouryon Chemicals International B.V. (NL) | 2024-12-04 | — | — | EP | disclosed |
| CN-119059951-A | Process for preparing peroxyesters or peroxycarbonates | 诺力昂化学品国际有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240309019-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-09-19 | — | — | US | disclosed |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240246986-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-07-25 | — | — | US | disclosed |
| US-12018122-B2 | Method for producing silane-modified polymers | MERZ+BENTELI AG (CH) | 2024-06-25 | — | — | US | disclosed |
| WO-2024125600-A1 | HETEROCYCLIC COMPOUNDS ACTING AS KRAS INHIBITORS, PREPARATION THEREFOR AND THERAPEUTIC USE THEREOF | 上海科州药物研发有限公司 | 2024-06-20 | — | — | WO | disclosed |
| CN-114436978-B | Antifungal compound and application thereof | 中国人民解放军海军军医大学 | 2024-06-18 | — | — | CN | disclosed |
| US-20240186580-A1 | LITHIUM (N-CARBONYL)SULFONAMIDE COMPOUND, ADDITIVE FOR LITHIUM SECONDARY BATTERY, NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY, LITHIUM SECONDARY BATTERY PRECURSOR, LITHIUM SECONDARY BATTERY, AND METHOD FOR PRODUCING LITHIUM SECONDARY BATTERY | MITSUI CHEMICALS, INC. (JP) | 2024-06-06 | — | — | US | disclosed |
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-05-09 | — | — | US | disclosed |
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-19 | — | — | US | disclosed |
| EP-4320128-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4310073-A1 | LITHIUM (N-CARBONYL)SULFONAMIDE COMPOUND, ADDITIVE FOR LITHIUM SECONDARY BATTERY, NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY, LITHIUM SECONDARY BATTERY PRECURSOR, LITHIUM SECONDARY BATTERY, AND METHOD FOR PRODUCING LITHIUM SECONDARY BATTERY | Mitsui Chemicals, Inc. (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-11851438-B2 | 1′-cyano nucleoside analogs and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-11845755-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230391731-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | LIANGJIANG MEDICINE CO., LTD. (CN) | 2023-12-07 | — | — | US | disclosed |
| CN-111592536-B | Monocyclic beta-lactam compound, preparation method and application thereof | 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） | 2023-11-03 | — | — | CN | disclosed |
| CN-116981656-A | Lithium (N-carbonyl) sulfonamide compound, additive for lithium secondary battery, nonaqueous electrolyte for lithium secondary battery, lithium secondary battery precursor, lithium secondary battery, and method for producing lithium secondary battery | 三井化学株式会社 | 2023-10-31 | — | — | CN | disclosed |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230295172-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230279013-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2023167944-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-09-07 | — | — | US | disclosed |
| EP-4232437-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | Liangjiang Medicine Co., Ltd. (CN) | 2023-08-30 | — | — | EP | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-116529252-A | Prodrugs for sustained release of therapeutic agents and uses thereof | 重庆两江药物研发中心有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-3877438-B1 | METHOD FOR THE PREPARATION OF SILANE-MODIFIED POLYMERS | MERZ BENTELI AG (CH) | 2023-06-14 | — | — | EP | disclosed |
| CN-113166358-B | Process for preparing silane-modified polymers | 默兹奔特利股份公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| WO-2022234470-A1 | NOVEL FUSED HETEROCYCLIC COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | PI INDUSTRIES LTD. (IN) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022196230-A1 | LITHIUM (N-CARBONYL)SULFONAMIDE COMPOUND, ADDITIVE FOR LITHIUM SECONDARY BATTERY, NON-AQUEOUS ELECTROLYTE FOR LITHIUM SECONDARY BATTERY, LITHIUM SECONDARY BATTERY PRECURSOR, LITHIUM SECONDARY BATTERY, AND METHOD FOR PRODUCING LITHIUM SECONDARY BATTERY | 三井化学株式会社 | 2022-09-22 | — | — | WO | disclosed |
| CN-114436978-A | Antifungal compound and application | 中国人民解放军海军军医大学 | 2022-05-06 | — | — | CN | disclosed |
| WO-2022083679-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | LIANGJIANG MEDICINE CO., LTD. (CN) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022083679-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | LIANGJIANG MEDICINE CO., LTD. (CN) | 2022-04-28 | — | — | WO | disclosed |
| CN-109456324-B | Isoindoline or isoquinoline compounds, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2022-04-22 | — | — | CN | disclosed |
| CN-109689664-B | Tricyclic heteroaryl substituted quinoline and azaquinoline compounds as PAR4 inhibitors | 百时美施贵宝公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20220072138-A1 | NRTI THERAPIES | THE JOHNS HOPKINS UNIVERSITY | 2022-03-10 | — | — | US | disclosed |
| US-20220024891-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-27 | — | — | US | disclosed |
| US-20210395450-A1 | METHOD FOR PRODUCING SILANE-MODIFIED POLYMERS | MERZ+BENTELI AG (CH) | 2021-12-23 | — | — | US | disclosed |
| EP-3897740-A1 | NRTI THERAPIES | THE UNIVERSITY OF LIVERPOOL (GB) | 2021-10-27 | — | — | EP | disclosed |
| EP-3890715-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | The Board Of Regents Of The University Of Texas System (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3683222-B1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-10-06 | — | — | EP | disclosed |
| CN-113474008-A | NRTI therapy | 利物浦大学 | 2021-10-01 | — | — | CN | disclosed |
| EP-3877438-A1 | METHOD FOR PRODUCING SILANE-MODIFIED POLYMERS | merz+benteli ag (CH) | 2021-09-15 | — | — | EP | disclosed |
| CN-113166358-A | Process for preparing silane-modified polymers | 默兹奔特利股份公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210188877-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-24 | — | — | US | disclosed |
| US-11028070-B2 | Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2021-06-08 | — | — | US | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210087172-A1 | FACTOR XIIa INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210070756-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200291027-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| CN-111592536-A | Monocyclic beta-lactam compound and preparation method and application thereof | 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） | 2020-08-28 | — | — | CN | disclosed |
| US-20200262816-A1 | ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2020-08-20 | — | — | US | disclosed |
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3484894-B1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3683222-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2020-07-22 | — | — | EP | disclosed |
| WO-2020128525-A1 | NRTI THERAPIES | THE UNIVERSITY OF LIVERPOOL (GB) | 2020-06-25 | — | — | WO | disclosed |
| US-10689364-B2 | Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2020-06-23 | — | — | US | disclosed |
| WO-2020117972-A1 | THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-06-11 | — | — | WO | disclosed |
| EP-3486231-B1 | PYRROLIDINE DERIVATIVE SERVING AS PPAR AGONIST | GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019233457-A1 | ERK INHIBITOR AND USE THEREOF | 贝达药业股份有限公司 (CN) | 2019-12-12 | — | — | WO | disclosed |
| US-20190315774-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| EP-3539962-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| CN-105431422-B | Isoindoline or isoquinoline compounds, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2019-08-30 | — | — | CN | disclosed |
| US-20190225597-A1 | PYRROLIDINE DERIVATIVES AS PPAR AGONISTS | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-07-25 | — | — | US | disclosed |
| CN-110003118-A | The method for preparing carboxylic ester derivative | 阿达玛马克西姆股份有限公司 | 2019-07-12 | — | — | CN | disclosed |
| EP-3484894-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-3484878-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | Bristol-Myers Squibb Company (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-3486231-A1 | PYRROLIDINE DERIVATIVE SERVING AS PPAR AGONIST | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-05-22 | — | — | EP | disclosed |
| EP-2970330-B1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2019-04-17 | — | — | EP | disclosed |
| CN-109456324-A | New isoindoline or isoquinoline compound, preparation method and the Pharmaceutical composition containing them | 法国施维雅药厂 | 2019-03-12 | — | — | CN | disclosed |
| CN-104902757-B | N- (substituted) -5-fluoro-4-imino-3-methyl-2-oxo-3, 4-dihydropyrimidine-1 (2H) -carboxylate derivatives | 阿达玛马克西姆股份有限公司 | 2019-01-08 | — | — | CN | disclosed |
| EP-3024826-B1 | NEW ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2018-11-14 | — | — | EP | disclosed |
| US-20180298003-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-18 | — | — | US | disclosed |
| US-10065972-B2 | Bicyclic or tricyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-09-04 | — | — | US | disclosed |
| EP-2502907-B1 | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2018-08-29 | — | — | EP | disclosed |
| US-10035800-B2 | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | ABBVIE INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180064665-A1 | N-PHENYL-N'-PHENOXYCARBONYL-PHENYLSULFONHYDRAZIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) | 2018-03-08 | — | — | US | disclosed |
| US-9908855-B2 | N-(substituted)-5-fluoro-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidine-1(2H)-carboxylate derivatives | ADAMA MAKHTESHIM LTD. (IL) | 2018-03-06 | — | — | US | disclosed |
| WO-2018013776-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
| EP-3269709-A1 | N-PHENYL-N'-PHENOXYCARBONYL-PHENYLSULFONHYDRAZIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) | 2018-01-17 | — | — | EP | disclosed |
| US-20180002313-A1 | ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2018-01-04 | — | — | US | disclosed |
| EP-2518052-B1 | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-9809574-B2 | Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-11-07 | — | — | US | disclosed |
| US-20170204069-A1 | N-(SUBSTITUTED)-5-FLUORO-4-IMINO-3-METHYL-2-OXO-3,4-DIHYDROPYRIMIDINE-1(2H)-CARBOXYLATE DERIVATIVES | ADAMA MAKHTESHIM LTD. (IL) | 2017-07-20 | — | — | US | disclosed |
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-9622474-B2 | N-(substituted)-5-fluoro-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidine-1(2H)-carboxylate derivatives | ADAMA MAKHTESHIM LTD. (IL) | 2017-04-18 | — | — | US | disclosed |
| EP-3135674-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-9573911-B2 | Diphosphate mimetics and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573911-B2 | Diphosphate mimetics and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160376289-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-29 | — | — | US | disclosed |
| EP-2744812-B1 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-07-20 | — | — | EP | disclosed |
| US-9387254-B2 | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | PROLYNX LLC (US) | 2016-07-12 | — | — | US | disclosed |
| US-20160194304-A1 | ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2016-07-07 | — | — | US | disclosed |
| US-20160192653-A1 | N-(SUBSTITUTED)-5-FLUORO-4-IMINO-3-METHYL-2-OXO-3,4-DIHYDROPYRIMIDINE-1(2H)-CARBOXYLATE DERIVATIVES | ADAMA MAKHTESHIM LTD. (IL) | 2016-07-07 | — | — | US | disclosed |
| EP-3024826-A1 | NEW ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Les Laboratoires Servier (FR) | 2016-06-01 | — | — | EP | disclosed |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160039821-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC. | 2016-02-11 | — | — | US | disclosed |
| US-9227984-B2 | Therapeutically active fused pyrimidine derivatives | UCB PHARMA S.A. (BE) | 2016-01-05 | — | — | US | disclosed |
| US-9226916-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227940-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| EP-2938194-A1 | N-(SUBSTITUTED)-5-FLUORO-4-IMINO-3-METHYL-2-OXO-3,4-DIHYDROPYRIMIDINE-1 (2H)-CARBOXYLATE DERIVATIVES | Dow AgroSciences LLC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-1595870-B1 | PROCESS FOR PRODUCING PHENYLALANINE DERIVATIVE HAVING QUINAZOLINEDIONE SKELETON AND INTERMEDIATE FOR THE SAME | AJINOMOTO KK (JP) | 2015-09-23 | — | — | EP | disclosed |
| EP-2210886-B1 | PYRIMIDYL INDOLINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-09-23 | — | — | EP | disclosed |
| CN-104902757-A | N- (substituted) -5-fluoro-4-imino-3-methyl-2-oxo-3, 4-dihydropyrimidine-1 (2H) -carboxylate derivatives | DOW AGROSCIENCES LLC | 2015-09-09 | — | — | CN | disclosed |
| WO-2015011164-A1 | NEW ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2015-01-29 | — | — | WO | disclosed |
| US-20150005342-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-01-01 | — | — | US | disclosed |
| US-8889871-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140309222-A1 | Therapeutically Active Fused Pyrimidine Derivatives | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2014-10-16 | — | — | US | disclosed |
| US-20140296476-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | PROLYNX LLC | 2014-10-02 | — | — | US | disclosed |
| WO-2014105844-A1 | N-(SUBSTITUTED)-5-FLUORO-4-IMINO-3-METHYL-2-OXO-3,4-DIHYDROPYRIMIDINE-1 (2H)-CARBOXYLATE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2014-07-03 | — | — | WO | disclosed |
| EP-2744812-A2 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB Pharma, S.A. (BE) | 2014-06-25 | — | — | EP | disclosed |
| US-20140163231-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163079-A1 | DIPHOSPHATE MIMETICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163079-A1 | DIPHOSPHATE MIMETICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2513052-B1 | PYRROLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-06-04 | — | — | EP | disclosed |
| US-20140142074-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-05-22 | — | — | US | disclosed |
| US-20140142074-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-05-22 | — | — | US | disclosed |
| US-8710229-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2260021-B1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-04-23 | — | — | EP | disclosed |
| EP-1684787-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8680315-B2 | Prodrugs and drug-macromolecule conjugates having controlled drug release rates | PROLYNX, LLC (US) | 2014-03-25 | — | — | US | disclosed |
| US-20130267713-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-10-10 | — | — | US | disclosed |
| US-8546610-B2 | Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of the derivatives | AJINOMOTO CO., INC. (JP) | 2013-10-01 | — | — | US | disclosed |
| US-8513424-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513265-B2 | [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-20 | — | — | US | disclosed |
| US-8507722-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130184249-A1 | PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-07-18 | — | — | US | disclosed |
| CN-1668288-B | Compounds with antiparasitic activity and medicaments containing them | CENTRE NAT RECH SCIENT | 2013-07-17 | — | — | CN | disclosed |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | HORIKOSHI, HIROYOSHI (CA) | 2013-06-27 | — | — | US | disclosed |
| US-20130116237-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-09 | — | — | US | disclosed |
| US-RE44205-E1 | Adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2581373-A1 | BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE | Fujita, Takashi (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-8420851-B2 | Selective TR-β 1 agonist | CADILA HEALTHCARE LIMITED (IN) | 2013-04-16 | — | — | US | disclosed |
| US-20130079313-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-03-28 | — | — | US | disclosed |
| US-20130079313-A1 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-03-28 | — | — | US | disclosed |
| US-8399674-B2 | Quinolines | HOFFMAN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| WO-2013024291-A2 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2013-02-21 | — | — | WO | disclosed |
| US-8372860-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8367694-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| WO-2013006758-A1 | DIPHOSPHATE MIMETICS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-01-10 | — | — | WO | disclosed |
| US-20120330019-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-27 | — | — | US | disclosed |
| EP-2079678-B1 | SELECTIVE TR-BETA 1 AGONIST | CADILA HEALTHCARE LTD (IN) | 2012-12-19 | — | — | EP | disclosed |
| EP-1737461-B1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2012-12-12 | — | — | EP | disclosed |
| US-8318975-B2 | Methods for producing phenylalanine derivatives having a quinazolinedione skeleton and intermediates for production thereof | AJINOMOTO CO., INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8314095-B2 | [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2518052-A1 | Substituted 4-aminocyclohexane derivatives | Grünenthal GmbH (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-8299094-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2513052-A1 | PYRROLIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| WO-2012140490-A2 | PROCESS FOR PREPARING QUINOLINE DERIVATIVE | AUROBINDO PHARMA LIMITED (IN) | 2012-10-18 | — | — | WO | disclosed |
| EP-1910362-B1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120258959-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2012-10-11 | — | — | US | disclosed |
| US-8278343-B2 | Pyrrolidines | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2502907-A1 | Substituted 4-aminocyclohexane derivatives | Grünenthal GmbH (DE) | 2012-09-26 | — | — | EP | disclosed |
| US-20120202790-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-8232404-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232287-B2 | Pyrimidyl indoline compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-07-31 | — | — | US | disclosed |
| US-8222228-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-07-17 | — | — | US | disclosed |
| US-8222228-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-07-17 | — | — | US | disclosed |
| US-8222228-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-07-17 | — | — | US | disclosed |
| US-8212035-B2 | Process for preparation of rosuvastatin calcium field of the invention | AUROBINDO PHARMA LTD. (IN) | 2012-07-03 | — | — | US | disclosed |
| EP-2468752-A1 | Thiazolopyridine derivatives as sirtuin-modulators | Sirtris Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2468752-A1 | Thiazolopyridine derivatives as sirtuin-modulators | Sirtris Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20120136018-A1 | QUINOLINES | KOLCZEWSKI SABINE (DE) | 2012-05-31 | — | — | US | disclosed |
| US-8188284-B2 | 2-aminoquinolines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120129841-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2012-05-24 | — | — | US | disclosed |
| EP-2144902-B1 | [6,6]AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2012-05-16 | — | — | EP | disclosed |
| US-8178536-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178536-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8168647-B2 | Vinblastine derivatives, their preparation, use and pharmaceutical compositions comprising the said derivatives | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2012-05-01 | — | — | US | disclosed |
| US-8168647-B2 | Vinblastine derivatives, their preparation, use and pharmaceutical compositions comprising the said derivatives | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2012-05-01 | — | — | US | disclosed |
| US-8163908-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163908-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163908-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2431369-A2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC Therapeutics, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2103601-B1 | PROCESS FOR PRODUCTION OF PHENYLALANINE DERIVATIVES HAVING QUINAZOLINEDIONE SKELETONS AND INTERMEDIATES FOR THE PRODUCTION | AJINOMOTO KK (JP) | 2012-03-14 | — | — | EP | disclosed |
| EP-1871375-B1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PTC THERAPEUTICS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-1531810-B1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20120022254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-8097726-B2 | Huperzine a compound for treatment of alzheimer's disease | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2012-01-17 | — | — | US | disclosed |
| US-8093401-B2 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093401-B2 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093401-B2 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8088928-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088928-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088928-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110311482-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-22 | — | — | US | disclosed |
| US-20110313154-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF THE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2011-12-22 | — | — | US | disclosed |
| US-8076322-B2 | [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076352-B2 | Administration of carboline derivatives useful in the treatment of cancer and other diseases | PTC THERAPEUTICS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8067409-B2 | Protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2388263-A1 | Imidazo[2,1-b]thiazole derivatives as sirtuin modulators | Sirtris Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8058432-B2 | Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of derivatives | AJINOMOTO CO., INC. (JP) | 2011-11-15 | — | — | US | disclosed |
| US-20110263502-A1 | PRODRUGS AND DRUG-MACROMOLECULE CONJUGATES HAVING CONTROLLED DRUG RELEASE RATES | PROLYNX, LLC | 2011-10-27 | — | — | US | disclosed |
| US-8044198-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044198-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044198-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110251389-A1 | Process For Making N-(Diphenylmethyl)piperazines | ZHU JIE | 2011-10-13 | — | — | US | disclosed |
| US-20110245227-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| EP-1505963-B9 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2364296-A1 | PYRROLIDINES | Pfizer Limited (GB) | 2011-09-14 | — | — | EP | disclosed |
| EP-2170864-B1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-14 | — | — | EP | disclosed |
| US-8012985-B2 | parasiticides, in particularly against Plasmodium and babesia; antimalarial agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2011-09-06 | — | — | US | disclosed |
| US-8003796-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-23 | — | — | US | disclosed |
| US-7989623-B2 | Process for making n-(diphenylmethyl)piperazines | SYNTHON BV (NL) | 2011-08-02 | — | — | US | disclosed |
| WO-2011085886-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
| EP-2340830-A2 | Hepatitis C Virus Inhibitors | Bristol-Myers Squibb Company (US) | 2011-07-06 | — | — | EP | disclosed |
| US-20110160190-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110144081-A1 | PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
| US-20110136783-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-09 | — | — | US | disclosed |
| US-7956190-B2 | Benzimidazole amido derivatives as kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110130387-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130387-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130387-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7951793-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| US-20110091385-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110091385-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110091385-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2011-04-21 | — | — | US | disclosed |
| EP-1505963-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7919508-B2 | 3-piperidinylisochroman-5-ols as dopamine agonists | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919508-B2 | 3-piperidinylisochroman-5-ols as dopamine agonists | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7915291-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| EP-2298304-A2 | Carboline derivatives useful in the treatment of cancer | PTC Therapeutics, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-7910583-B2 | [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| EP-2284157-A1 | Quinolines useful in treating cardiovascular disease | Wyeth (US) | 2011-02-16 | — | — | EP | disclosed |
| US-7888329-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | PGXHEALTH, LLC (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888329-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | PGXHEALTH, LLC (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888329-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | PGXHEALTH, LLC (US) | 2011-02-15 | — | — | US | disclosed |
| US-7855289-B2 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855289-B2 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855289-B2 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2252372-A1 | 2-AMINOQUINOLINES | F. Hoffmann-La Roche AG (CH) | 2010-11-24 | — | — | EP | disclosed |
| US-20100292259-A1 | PYRIMIDYL INDOLINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| EP-1401433-B1 | AZOLE ACID DERIVATIVES, ALONE OR IN COMBINATION, FOR TREATING DIABETES AND DYSLIPIDEMIAS; AND FOR TREATING MALIGNANT DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2010-11-10 | — | — | EP | disclosed |
| US-7803785-B2 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| WO-2010100475-A1 | HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2010-09-10 | — | — | WO | disclosed |
| EP-2222682-A1 | IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Abbott Laboratories (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100216772-A1 | Novel Phenantridine Analogues and Uses Thereof | 4SC AG (DE) | 2010-08-26 | — | — | US | disclosed |
| US-20100204505-A1 | METHODS FOR PRODUCING PHENYLALANINE DERIVATIVES HAVING A QUINAZOLINEDIONE SKELETON AND INTERMEDIATES FOR PRODUCTION THEREOF | AJINOMOTO CO. INC (JP) | 2010-08-12 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7767689-B2 | Carboline derivatives useful in the treatment of cancer | PTC THERAPEUTICS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| EP-2210886-A1 | PYRIMIDYL INDOLINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-20100179132-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-7754866-B2 | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20100168181-A1 | BENZIMIDAZOLE AMIDO DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2010-07-01 | — | — | US | disclosed |
| EP-2195296-A1 | QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-06-16 | — | — | EP | disclosed |
| US-7737274-B2 | Methods for producing phenylalanine derivatives having a quinazolinedione skeleton and intermediates for production thereof | AJINOMOTO CO., INC. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-20100125065-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. | 2010-05-20 | — | — | US | disclosed |
| WO-2010052625-A1 | PYRROLIDINES | PFIZER LIMITED (GB) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120793-A1 | Pyrrolidines | PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100113498-A1 | NOVEL VINBLASTINE DERIVATIVES, THEIR PREPARATION, USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAID DERIVATIVES | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2010-05-06 | — | — | US | disclosed |
| US-20100113498-A1 | NOVEL VINBLASTINE DERIVATIVES, THEIR PREPARATION, USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAID DERIVATIVES | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2010-05-06 | — | — | US | disclosed |
| US-7696374-B2 | Arylalklcarbamate derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-04-13 | — | — | US | disclosed |
| EP-2170864-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-2170859-A1 | BENZIMIDAZOLE AMIDO DERIVATIVES AS KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-04-07 | — | — | EP | disclosed |
| EP-1749001-B1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMA INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20100048550-A1 | SELECTIVE TR-BETA 1 AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2010-02-25 | — | — | US | disclosed |
| EP-1303503-B1 | ANILINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20100016254-A1 | GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| EP-2144902-A1 | [6,6]AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090318688-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090312547-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM FIELD OF THE INVENTION | AUROBINDO PHARMA LTD (IN) | 2009-12-17 | — | — | US | disclosed |
| EP-2125754-A1 | AN IMPROVED PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM | Aurobindo Pharma Limited (IN) | 2009-12-02 | — | — | EP | disclosed |
| EP-2119720-A1 | NOVEL VINBLASTINE DERIVATIVES, THEIR PREPARATION, USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAID DERIVATIVES | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2009-11-18 | — | — | EP | disclosed |
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20090280059-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090280059-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090280059-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090274656-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| US-7608602-B2 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7601840-B2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090253723-A1 | PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| EP-2103601-A1 | PROCESS FOR PRODUCTION OF PHENYLALANINE DERIVATIVES HAVING QUINAZOLINEDIONE SKELETONS AND INTERMEDIATES FOR THE PRODUCTION | Ajinomoto Co., Inc. (JP) | 2009-09-23 | — | — | EP | disclosed |
| EP-1957571-B1 | STABILIZED THERMOPLASTIC COMPOSITION, METHOD OF MAKING, AND ARTICLES FORMED THEREFROM | GEN ELECTRIC (US) | 2009-09-16 | — | — | EP | disclosed |
| US-7589076-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | PGX HEALTH, LLC (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589076-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | PGX HEALTH, LLC (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589076-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | PGX HEALTH, LLC (US) | 2009-09-15 | — | — | US | disclosed |
| WO-2009109502-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227583-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2009-09-10 | — | — | US | disclosed |
| US-20090227618-A2 | Carboline Derivatives Useful in the Inhibition of Angiogenesis | PTC THERAPEUTICS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090227574-A2 | Administration of Carboline Derivatives Useful in the Treatment of Cancer and Other Diseases | PTC THERAPEUTICS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| EP-1656368-A4 | SUBSTITUTED HERTOCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7579479-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7576215-B2 | Quinolines and pharmaceutical compositions thereof | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1684787-A4 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-2079678-A2 | SELECTIVE TR-BETA 1 AGONIST | Cadila Healthcare Limited (IN) | 2009-07-22 | — | — | EP | disclosed |
| WO-2009070516-A1 | IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20090143582-A1 | Process for making n-(diphenylmethyl)piperazines | SYNTHON BV (NL) | 2009-06-04 | — | — | US | disclosed |
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| WO-2009065622-A1 | PROCESS FOR MAKING N-(DIPHENYLMETHYL)PIPERAZINES | SYNTHON B.V. (NL) | 2009-05-28 | — | — | WO | disclosed |
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| US-7531566-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090105230-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2009-04-23 | — | — | US | disclosed |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090088451-A1 | QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
| WO-2009040290-A1 | QUINOLINE DERIVATIVES AS 5HT5A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | WO | disclosed |
| US-7511092-B2 | bisphenol a type polycarbonates (e.g. polyesterpolycarbonate copolymer), pyrogallol tri-benzoate (PTB), and pyrogallol tri-phenyl carbonate (PTPC), and an ionization inhibitor ( 2-Methyl-2,4-pentanediol ); improved resistance to gamma-rays | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2009-03-31 | — | — | US | disclosed |
| US-7507757-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090076102-A1 | DEUTERIUM-ENRICHED MURAGLITAZAR | PROTIA, LLC (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090076102-A1 | DEUTERIUM-ENRICHED MURAGLITAZAR | PROTIA, LLC (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090076254-A1 | NON-ENDOGENOUS, CONSTITUTIVELY ACTIVATED HUMAN SEROTONIN RECEPTORS AND SMALL MOLECULE MODULATORS THEREOF | ARENA PHARMACEUTICALS INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090075986-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2009-03-19 | — | — | US | disclosed |
| EP-1858509-A4 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LTD (GB) | 2009-03-18 | — | — | EP | disclosed |
| EP-1501846-B1 | TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS | ABBOTT LAB (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-2024380-A2 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | Adenosine Therapeutics, LLC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-22 | — | — | US | disclosed |
| WO-2009012275-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| EP-1218361-B1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2009000489-A1 | BENZIMIDAZOLE AMIDO DERIVATIVES AS KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-31 | — | — | WO | disclosed |
| EP-1505963-A4 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080293690-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-27 | — | — | US | disclosed |
| US-7452907-B2 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| WO-2008137435-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
| US-7449479-B2 | Serine protease inhibition via 1-{[1-(2-Methoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1505945-B1 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-11-05 | — | — | EP | disclosed |
| CN-101282761-A | Benzimidazole derivatives as SIRTUIN modulators | SIRTRIS PHARMACEUTICALS INC (US) | 2008-10-08 | — | — | CN | disclosed |
| US-20080221157-A1 | Amide Derivatives as Inhibitors of Histone Deacetylase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGE (IT) | 2008-09-11 | — | — | US | disclosed |
| EP-1957571-A2 | STABILIZED THERMOPLASTIC COMPOSITION, METHOD OF MAKING, AND ARTICLES FORMED THEREFROM | General Electric Company (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2008096257-A1 | AN IMPROVED PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM | AUROBINDO PHARMA LIMITED (IN) | 2008-08-14 | — | — | WO | disclosed |
| US-20080187978-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2008-08-07 | — | — | US | disclosed |
| EP-1311475-B1 | AMINOCYCLOHEXANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-08-06 | — | — | EP | disclosed |
| EP-1939188-A1 | Oxa-and thiazole derivatives useful as antidiabetic and antiobesity agents | Bristol-Myers Squibb Company (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20080132506-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2008-06-05 | — | — | US | disclosed |
| WO-2008062469-A2 | SELECTIVE TR-BETA 1 AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2008-05-29 | — | — | WO | disclosed |
| EP-1531810-A4 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-7368539-B2 | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | ARENA PHARMACEUTICALS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-7365093-B2 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| US-7354905-B2 | Prodrugs of thrombin inhibitors | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| US-7345178-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345178-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20080064688-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2008-03-13 | — | — | US | disclosed |
| US-7342037-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-03-11 | — | — | US | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008027483-A1 | BENZOFURAN DERIVATIVES AS MODULATORS OF THE 5-HT2A RECEPTOR | ARENA PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| US-7335687-B2 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20080021208-A1 | Gemcitabine Prodrugs, Pharmaceutical Compositions and Uses Thereof | XENOPORT, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080015238-A1 | CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015238-A1 | CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-17 | — | — | US | disclosed |
| EP-1315729-B1 | COMPOUNDS IN THE FORM OF HOMODIMERIC OR HETERODIMERIC PRODRUGS; PROCESS FOR OBTAINING THESE PRODRUGS AND THEIR ACCEPTABLE PHARMACEUTICAL SALTS AND USE OF COMPOUNDS IN THE TREATMENT OF PHOSPHODIESTERASES-MEDIATED DISEASES OR DYSFUNCTION | CRISTALIA PROD QUIMICOS FARM (BR) | 2008-01-09 | — | — | EP | disclosed |
| EP-1871375-A2 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PCT Therapeutics Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| WO-2007136817-A2 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | ADENOSINE THERAPEUTICS, LLC (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070275956-A1 | Novel Heterocyclic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2007-11-29 | — | — | US | disclosed |
| EP-1858509-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| US-20070270454-A1 | Huperzine a compound for treatment of Alzheimer's disease | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2007-11-22 | — | — | US | disclosed |
| US-20070270373-A1 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | ADENOSINE THERAPEUTICS, LLC | 2007-11-22 | — | — | US | disclosed |
| US-20070270373-A1 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | ADENOSINE THERAPEUTICS, LLC | 2007-11-22 | — | — | US | disclosed |
| US-20070270373-A1 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | ADENOSINE THERAPEUTICS, LLC | 2007-11-22 | — | — | US | disclosed |
| US-20070254878-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. | 2007-11-01 | — | — | US | disclosed |
| US-7279485-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-09 | — | — | US | disclosed |
| US-7276511-B2 | Benzylamine derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2007-10-02 | — | — | US | disclosed |
| US-7276511-B2 | Benzylamine derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2007-10-02 | — | — | US | disclosed |
| US-7276511-B2 | Benzylamine derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2007-10-02 | — | — | US | disclosed |
| WO-2005089764-A9 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2007-09-13 | — | — | WO | disclosed |
| US-7265096-B2 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7259177-B2 | Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-21 | — | — | US | disclosed |
| US-7259177-B2 | Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-21 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| EP-1673092-B1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070117836-A1 | NAPTHALIMIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2007-05-24 | — | — | US | disclosed |
| US-20070112008-A1 | Saframycins, analogues and uses thereof | MYERS ANDREW G | 2007-05-17 | — | — | US | disclosed |
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-7208517-B1 | Endothelin antagonists | ABBOTT LABORTORIES (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
| WO-2007044303-A2 | STABILIZED THERMOPLASTIC COMPOSITION, METHOD OF MAKING, AND ARTICLES FORMED THEREFROM | GENERAL ELECTRIC COMPANY (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082989-A1 | Stabilized thermoplastic composition, method of making, and articles formed therefrom | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2007-04-12 | — | — | US | disclosed |
| US-7202257-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1768955-A1 | AMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-04-04 | — | — | EP | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1242059-B1 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | UNIV NORTH CAROLINA (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1120423-B1 | Improved chemiluminescent 1,2-dioxetanes | APPLERA CORP (US) | 2007-03-14 | — | — | EP | disclosed |
| US-7189756-B2 | Pyrrolidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019417-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRTIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRTIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRTIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | 4 AZA BIOSCIENCE NV (BE) | 2007-02-08 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| EP-1742920-A2 | NAPHTHALIMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | Unibioscreen S.A. (BE) | 2007-01-17 | — | — | EP | disclosed |
| EP-1737461-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC Therapeutics, Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| US-7153971-B2 | Contacting a carbohydrate with an amine to produce amino tetrahydroxy carbohydrate, protecting two hydroxy groups of tetrahydroxy carbohydrate, forming hydroxy heterocyclic-spiro moiety by reacting with activated carbonate, oxidizing OH | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006131828-A1 | A PROCESS FOR THE PREPARATION OF PERINDOPRIL | AUROBINDO PHARMA LIMITED (IN) | 2006-12-14 | — | — | WO | disclosed |
| US-7148350-B2 | Compounds in the form of homodimeric or heterodimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterases-mediated diseases or dysfunction | CRISTALIA PROD.QUI.FARM. LTDA (BR) | 2006-12-12 | — | — | US | disclosed |
| EP-1505945-A4 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-11-22 | — | — | EP | disclosed |
| US-7135462-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| WO-2006113703-A2 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | PTC THERAPEUTICS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| US-7122549-B2 | Saframycins, analogues and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-10-17 | — | — | US | disclosed |
| US-20060229280-A1 | Endothelin antagonists | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
| US-20060223805-A1 | Arylalklcarbamate derivatives, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2006-10-05 | — | — | US | disclosed |
| US-7115741-B2 | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds | ALEXION PHARMACEUTICALS, INC. | 2006-10-03 | — | — | US | disclosed |
| CN-1834091-A | Sustituted Gly derivative for treating diabetes and adiposis | SHENG ZELIN (CN) | 2006-09-20 | — | — | CN | disclosed |
| US-20060205772-A1 | Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type I | COPPOLA GARY M | 2006-09-14 | — | — | US | disclosed |
| US-7105556-B2 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-12 | — | — | US | disclosed |
| WO-2006094003-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2006-09-08 | — | — | WO | disclosed |
| US-20060194841-A1 | E.g., N-{2-(3,4-dichlorophenyl)-2-[(3,3-diphenylpropionyl)-methylamino]-4-{spiro[benzo(c)thiophene-1(3H),4'-piperidine]-(2S)-oxide}-1'-yl-butyl}-3,3,3-trifluoro-N-methyl-propionamide hydrochloride, NK-1 or NK-2 receptor antagonists; irritable bowel syndrome, pain, anxiety, COPD, headaches and vomiting | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| US-20060189598-A1 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2006-08-24 | — | — | US | disclosed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060172950-A1 | Serine protease inhibition via 1-{[1-(2-Methoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid | WANG XIANGDONG A | 2006-08-03 | — | — | US | disclosed |
| EP-1684787-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-08-02 | — | — | EP | disclosed |
| US-7084162-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-01 | — | — | US | disclosed |
| US-7078553-B2 | Dehydrohalogenation by reacting a di-hydroperoxy compound with an acid halogen or halogen formate to form mono- or di-peroxy ester or carbonate; polymerization initiators, curing agents for unsaturated polyesters and modifying agents | AKZO NOBEL N.V. (NL) | 2006-07-18 | — | — | US | disclosed |
| EP-1673092-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA Bioscience nv (BE) | 2006-06-28 | — | — | EP | disclosed |
| US-7067655-B2 | preparation of furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl, phenyl, pyrrolyl or C4-C6 cycloalkenyl- substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosines prepared from 2-amino-4,6-dihydroxypyrimidine, POCl3 and dimethylformamide | SCHERING CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-7064218-B2 | Aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-7053106-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1656368-A2 | SUBSTITUTED HERTOCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1650189-A1 | BENZYLAMINE DERIVATIVE | Zeria Pharmaceutical Co., Ltd. (JP) | 2006-04-26 | — | — | EP | disclosed |
| EP-0885215-B1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LAB (US) | 2006-04-19 | — | — | EP | disclosed |
| US-7030138-B2 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-23 | — | — | US | disclosed |
| US-7015345-B2 | Propionic acid derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-03-21 | — | — | US | disclosed |
| EP-1622610-A1 | 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | Aventis Pharmaceuticals Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1358162-B1 | DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-02-08 | — | — | EP | disclosed |
| US-6995174-B2 | for inhibiting proteases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-07 | — | — | US | disclosed |
| US-6992069-B2 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2006-01-31 | — | — | US | disclosed |
| US-20060014750-A1 | Pharmaceutical compositions for the treatment of CNS and other disorders | PFIZER INC | 2006-01-19 | — | — | US | disclosed |
| WO-2006005941-A1 | AMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI S.P.A. (IT) | 2006-01-19 | — | — | WO | disclosed |
| US-20060009476-A1 | Methods for producing phenylalanine derivatives having a quinazolinedione skeleton and intermediates for production thereof | AJINOMOTO CO. INC (JP) | 2006-01-12 | — | — | US | disclosed |
| US-20050288343-A1 | Process of preparing substituted carbamates and intermediates thereof | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
| US-20050288286-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2005-12-29 | — | — | US | disclosed |
| EP-1609790-A2 | Benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists | Abbott Laboratories (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050282849-A1 | Carboline derivatives useful in the treatment of cancer | PTC THERAPEUTICS, INC. | 2005-12-22 | — | — | US | disclosed |
| US-20050272759-A1 | Carboline derivatives useful in the inhibition of angiogenesis | PTC THERAPEUTICS, INC. | 2005-12-08 | — | — | US | disclosed |
| WO-2005113521-A1 | PROCESS OF PREPARING SUBSTITUTED CARBAMATES AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050267040-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | disclosed |
| EP-1595870-A1 | PROCESS FOR PRODUCING PHENYLALANINE DERIVATIVE HAVING QUINAZOLINEDIONE SKELETON AND INTERMEDIATE FOR THE SAME | Ajinomoto Co., Inc. (JP) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005105753-A2 | NAPHTHALIMIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2005-11-10 | — | — | WO | disclosed |
| EP-1590319-A1 | AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Novartis AG (CH) | 2005-11-02 | — | — | EP | disclosed |
| EP-1589006-A1 | Oxa- and thiazole derivatives useful as antidiabetics and antidiobesity agents | Bristol-Myers Squibb Company (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1401433-A4 | CONFORMATIONALLY CONSTRAINED ANALOGS USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2005-10-12 | — | — | EP | disclosed |
| US-6953788-B1 | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-11 | — | — | US | disclosed |
| WO-2005089764-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050209195-A1 | Indolinone derivatives | CELL THERAPEUTICS EUROPE S.R.I (IT) | 2005-09-22 | — | — | US | disclosed |
| US-6946481-B1 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2005-09-20 | — | — | US | disclosed |
| CN-1668288-A | Compounds with antiparasitic activity and medicaments containing them | CENTRE NAT RECH SCIENT (FR) | 2005-09-14 | — | — | CN | disclosed |
| CN-1665500-A | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL MYERS SQUIBB CO (US) | 2005-09-07 | — | — | CN | disclosed |
| EP-1567169-A2 | GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20050176819-A1 | Compounds with antiparasitic activity and medicines containing same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N. (FR) | 2005-08-11 | — | — | US | disclosed |
| US-20050176766-A1 | 2,3-Oxidosqualene-lanosterol cyclase inhibitors | ACKERMANN JEAN (CH) | 2005-08-11 | — | — | US | disclosed |
| WO-2005051410-A9 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005068424-A1 | INDOLINONE DERIVATIVES AS RECEPTOR TYROSINE KINASE IHIBITORS | CELL THERAPEUTICS EUROPE S.R.L. (IT) | 2005-07-28 | — | — | WO | disclosed |
| US-6919358-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
| US-6906103-B2 | Compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| WO-2005051410-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005049589-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA, DIABETES, OBESITY AND SIMILAR DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2005-06-02 | — | — | WO | disclosed |
| US-20050119311-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2005-06-02 | — | — | US | disclosed |
| US-20050119182-A1 | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | ARENA PHARMACEUTICALS, INC. (US) | 2005-06-02 | — | — | US | disclosed |
| US-20050119312-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2005-06-02 | — | — | US | disclosed |
| US-20050113346-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH HOLDINGS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| EP-1533318-A1 | Prodrugs of thrombin inhibitors | AstraZeneca AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| EP-1531810-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6897216-B2 | Adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2005-05-24 | — | — | US | disclosed |
| WO-2005039587-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA BIOSCIENCE NV (BE) | 2005-05-06 | — | — | WO | disclosed |
| EP-1283839-B1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1317460-A4 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | UNIV COLORADO STATE RES FOUND (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6878722-B2 | Substituted cycloalkyl P1′ hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-6875782-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| EP-0869966-B1 | PRODRUGS OF THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| EP-1509505-A2 | SMALL MOLECULE MODULATORS OF THE 5−HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| EP-1226128-B1 | NEW PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2005-02-23 | — | — | EP | disclosed |
| US-6858651-B2 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1505963-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1505945-A2 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20050026932-A1 | Adenosine A2a receptor antagonists | SCHERING CORPORATION | 2005-02-03 | — | — | US | disclosed |
| EP-1501846-A1 | TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS | Abbott Laboratories (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6849713-B2 | Compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-6846919-B2 | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-6835724-B2 | Topical antiinflammatory agents for treating inflammatory dermatoses | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-28 | — | — | US | disclosed |
| US-20040260111-A1 | Dehydrohalogenation by reacting a di-hydroperoxy compound with an acid halogen or halogen formate to form mono- or di-peroxy ester or carbonate; polymerization initiators, curing agents for unsaturated polyesters and modifying agents | VAN DE BOVENKAMP-BOUWMAN ANNA (NL) | 2004-12-23 | — | — | US | disclosed |
| EP-1484316-A1 | NOVEL PROPIONIC ACID DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2004-12-08 | — | — | EP | disclosed |
| EP-1482940-A2 | PRODRUGS OF SUBSTITUTED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040242672-A1 | Useful as inhibitors of metalloproteases, e.g. zinc proteases; effective in treating disease states associated with vasoconstriction such as high blood pressure, coronary disorders, cardiac insufficiency, renal and myocardial ischaemia, renal insufficiency, dialysis, cerebral ischaemia | AEBI JOHANNES (CH) | 2004-12-02 | — | — | US | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| US-6812227-B2 | SULFUR COMPOUNDS SUCH AS 2-((4-BUT-2-YNYLOXY-BENZENESULFONYL)-METHYL-AMINO)-N-HYDROXY-3-METHYL -BUTYRAMIDE, USED AS TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE) INHIBITORS, FOR PROPHYLAXIS OF RHEUMATIC DISEASES, SEPSIS OR INFLAMMATION | WYETH HOLDINGS CORPORATION | 2004-11-02 | — | — | US | disclosed |
| US-6809099-B2 | FOR THERAPY OF CANCER | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-10-26 | — | — | US | disclosed |
| US-20040204419-A1 | Saframycins, analogues and uses thereof | MYERS ANDREW G (US) | 2004-10-14 | — | — | US | disclosed |
| US-6790860-B2 | USEFUL AS INHIBITORS OF METALLOPROTEASES, E.G. ZINC PROTEASES; EFFECTIVE IN TREATING DISEASE STATES ASSOCIATED WITH VASOCONSTRICTION | HOFFMANN-LA ROCHE INC. | 2004-09-14 | — | — | US | disclosed |
| US-20040171644-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2004-09-02 | — | — | US | disclosed |
| US-20040162410-A1 | Prodrugs of thrombin inhibitors | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | US | disclosed |
| WO-2004065351-A1 | AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | NOVARTIS AG (CH) | 2004-08-05 | — | — | WO | disclosed |
| EP-1442028-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | Bristol-Myers Squibb Company (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-1071662-B1 | PEROXIDES, THEIR PREPARATION PROCESS AND USE | AKZO NOBEL NV (NL) | 2004-08-04 | — | — | EP | disclosed |
| CN-1517791-A | Colour photographic element containing improved heterocydic film speed raising compound | ��˹���´﹫˾ | 2004-08-04 | — | — | CN | disclosed |
| US-6770640-B1 | EMPHYSEMA | AVENTIS PHARMACEUTICALS INC. | 2004-08-03 | — | — | US | disclosed |
| US-6770774-B2 | USING A PEROXY COMPOUND AS CURING AGENT, POLYMERIZATION CATALYST | AKZO NOBEL N.V. (NL) | 2004-08-03 | — | — | US | disclosed |
| US-20040147560-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2004-07-29 | — | — | US | disclosed |
| US-20040147555-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20040142857-A1 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | XENOPORT, INC. | 2004-07-22 | — | — | US | disclosed |
| EP-1144368-B1 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | WYETH CORP (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20040106559-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
| US-6743790-B2 | A UREA OR THIOUREA DERIVATIVES CONTAINING AMIDE GROUP USEFUL AS ANTICOAGULANTS AND ANTIINFLAMMATORY AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-01 | — | — | US | disclosed |
| WO-2004043339-A2 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| EP-1421071-A2 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-26 | — | — | EP | disclosed |
| WO-2004041203-A2 | GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040082585-A1 | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | disclosed |
| US-6727271-B2 | OXAZOLE OR THIAZOLE DERIVATIVES; ANTILIPEMIC AGENTS, HYPOTENSIVES, ANTINEOPLASTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-27 | — | — | US | disclosed |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| EP-1071701-A4 | NON-ENDOGENOUS, CONSTITUTIVELY ACTIVATED HUMAN SEROTONIN RECEPTORS AND SMALL MOLECULE MODULATORS THEREOF | ARENA PHARM INC (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20040072690-A1 | Novel propionic acid derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-04-15 | — | — | US | disclosed |
| US-6716833-B2 | RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, SEPSIS, AIDS, ULCERATIVE COLITIS, MULTIPLE SCLEROSIS, CROHN'S DISEASE AND DEGENERATIVE CARTILAGE LOSS. | WYETH HOLDINGS CORPORATION | 2004-04-06 | — | — | US | disclosed |
| US-20040063700-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| US-20040063762-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| EP-1401433-A2 | CONFORMATIONALLY CONSTRAINED ANALOGS USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | Bristol-Myers Squibb Company (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-1047695-B1 | NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| US-20040039209-A1 | Compounds containing oxazolidinone moiety and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-02-26 | — | — | US | disclosed |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2004-02-19 | — | — | US | disclosed |
| US-20040034076-A1 | Novel carbamates and carbamides, production and use thereof as endothelin receptor antagonists | ABBOTT GMBH & CO. KG (DE) | 2004-02-19 | — | — | US | disclosed |
| US-20040029818-A1 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2004-02-12 | — | — | US | disclosed |
| US-20040023997-A1 | Adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. | 2004-02-05 | — | — | US | disclosed |
| US-20040019039-A1 | Substituted piperazines and diazepanes | HIGH POINT PHARMACEUTICALS, LLC | 2004-01-29 | — | — | US | disclosed |
| WO-2004004665-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004004655-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
| US-6673815-B2 | MODULATE BLOOD GLUCOSE LEVELS, TRIGLYCERIDE LEVELS, INSULIN LEVELS AND NON-ESTERIFIED FATTY ACID LEVELS | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-06 | — | — | US | disclosed |
| EP-1375482-A1 | BENZAMIDINE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-20030224442-A1 | Non-endogeneous, constitutively activated human serotonin receptors and small molecule modualtors thereof | BEHAN DOMINIC P (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| US-6653314-B2 | Modulate blood glucose levels, triglyceride levels, insulin levels and non-esterified fatty acid levels | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-25 | — | — | US | disclosed |
| US-6649652-B2 | Hypotensive agents; hyperglycemic agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-11-18 | — | — | US | disclosed |
| US-20030212113-A1 | Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | GLAXOSMITHKLINE LLC | 2003-11-13 | — | — | US | disclosed |
| WO-2003093289-A1 | TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2003-11-13 | — | — | WO | disclosed |
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH (US) | 2003-11-13 | — | — | US | disclosed |
| US-20030199569-A1 | Pyrrolidine derivatives | AEBI JOHANNES (CH) | 2003-10-23 | — | — | US | disclosed |
| US-20030199698-A1 | Carbamic acid esters as inhibitors of factor xa | MERCK PATENT GMBH (DE) | 2003-10-23 | — | — | US | disclosed |
| US-6630475-B2 | 5-amino-pyrazolo-(4, 3-e)-1,2,4-triazolo(1,5-c)pyrimidine adenosine A2a receptor antagonists; use in the treatment of central nervous system diseases, in particular Parkinson's disease | SCHERING CORPORATION | 2003-10-07 | — | — | US | disclosed |
| US-20030187037-A1 | Acetamide derivatives and the use thereof as inhibitors of coagulation factors xa and viia | MERCK-PATENT GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| US-20030171579-A1 | Urethane derivatives | MERCK PATENT GMBH (DE) | 2003-09-11 | — | — | US | disclosed |
| EP-1140818-B1 | AMIDOMALONAMIDES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMA INC (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030166694-A1 | Glycinamides | MERCK PATENT GMBH (DE) | 2003-09-04 | — | — | US | disclosed |
| EP-1339713-A2 | SAFRAMYCINS, ANALOGUES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | CELLTECH R&D LIMITED (GB) | 2003-08-28 | — | — | US | disclosed |
| US-20030153004-A1 | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | ARENA PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2003062206-A2 | SMALL MOLECULE MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| US-6596723-B1 | Compounds that are efflux pump inhibitors and therefore are useful as potentiators of anti-fungal agents for the treatment of infections caused by fungi that employ an efflux pump resistance mechanism. | ESSENTIAL THERAPEUTICS, INC. | 2003-07-22 | — | — | US | disclosed |
| WO-2003057212-A1 | POLYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030130306-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-10 | — | — | US | disclosed |
| US-20030119749-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | SMITHKLINE BEECHAM CORPORATION | 2003-06-26 | — | — | US | disclosed |
| EP-1317460-A1 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2003-06-11 | — | — | EP | disclosed |
| EP-1028721-B1 | N,N'-BIS(SULFONYL)HYDRAZINES USEFUL AS ANTINEOPLASTIC AGENTS | UNIV YALE (US) | 2003-06-04 | — | — | EP | disclosed |
| US-20030096846-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2003-05-22 | — | — | US | disclosed |
| EP-1311475-A1 | NOVEL AMINOCYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-21 | — | — | EP | disclosed |
| WO-2003040114-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-15 | — | — | WO | disclosed |
| US-20030092755-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-15 | — | — | US | disclosed |
| US-20030092697-A1 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-15 | — | — | US | disclosed |
| US-20030087935-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2003-05-08 | — | — | US | disclosed |
| EP-1303486-A1 | PYRROLIDINE DERIVATIVES AS METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-6552215-B1 | Reacting a hydroperoxy compound containing a peroxyester or peroxycarbonate functionality with an alkyl vinyl ether; polymerization initiators, curing agents for unsaturated polyesters and modifying agents | AKZO NOBEL N.V. (NL) | 2003-04-22 | — | — | US | disclosed |
| US-20030073861-A1 | Using a peroxy compound as curing agent, polymerization catalyst | VAN DE BOVENKAMP-BOUWMAN ANNA (NL) | 2003-04-17 | — | — | US | disclosed |
| US-20030069275-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T (US) | 2003-04-10 | — | — | US | disclosed |
| WO-2003028729-A2 | PRODRUGS OF SUBSTITUTED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
| EP-1299354-A2 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | Aventis Pharma Deutschland GmbH (DE) | 2003-04-09 | — | — | EP | disclosed |
| US-6544980-B2 | For treating neoplasms, atherosclerosis, and chronic inflammatory diseases | AVENTIS PHARMACEUTICALS INC. | 2003-04-08 | — | — | US | disclosed |
| US-6541209-B1 | Bioassay; identification of compounds as agonists; use in treatment of diseases and disorders that are related to 5-HT2A and or 5-HT2C serotonin receptors | ARENA PHARMACEUTICALS, INC. | 2003-04-01 | — | — | US | disclosed |
| EP-1294713-A2 | COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2003022214-A2 | PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-1049668-B1 | KETONE PEROXIDE DERIVATIVES, THEIR PREPARATION AND USE | AKZO NOBEL NV (NL) | 2003-03-19 | — | — | EP | disclosed |
| WO-2002000650-A9 | NOVEL COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECH INC (US) | 2003-03-06 | — | — | WO | disclosed |
| EP-1150976-B1 | 3-(THIO-SUBSTITUTED AMIDO)-LACTAMS USEFUL AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMA INC (US) | 2003-02-26 | — | — | EP | disclosed |
| EP-1283839-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-02-19 | — | — | EP | disclosed |
| EP-1140984-B1 | SELECTIVE INHIBITORS OF MMP-12 | AVENTIS PHARMA INC (US) | 2003-02-12 | — | — | EP | disclosed |
| US-6518283-B1 | To modify integrin function in such a way as to beneficially modulate cell adhesion | CELLTECH R&D LIMITED (GB) | 2003-02-11 | — | — | US | disclosed |
| WO-2003004480-A2 | SUBSTITUTED PIPERAZINE AND DIAZEPANES AS HISTAMINE H3 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | LEVIN JEREMY I (US) | 2003-01-09 | — | — | US | disclosed |
| US-20030008873-A1 | Saframycins, analogues and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
| US-6503940-B2 | Aids therapy | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-01-07 | — | — | US | disclosed |
| US-6498252-B1 | Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds | HOFFMANN-LA ROCHE INC. | 2002-12-24 | — | — | US | disclosed |
| WO-2002096357-A2 | CONFORMATIONALLY CONSTRAINED ANALOGS USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-0928291-B1 | 3-MERCAPTOACETYLAMINO-1,5-SUBSTITUTED-2-OXO-AZEPAN DERIVATIVES USEFUL AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMA INC (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020177591-A1 | Pharmaceutical compositions for the treatment of CNS and other discorders | PFIZER INC. | 2002-11-28 | — | — | US | disclosed |
| US-6486200-B1 | Prodrugs for antimicrobial amidines | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2002-11-26 | — | — | US | disclosed |
| US-6486193-B2 | ANTIARTHRITIC AGENTS; ANTIINFLAMMATORY AGENTS | AVENTIS PHARMACEUTICALS INC. | 2002-11-26 | — | — | US | disclosed |
| US-6482970-B1 | Peroxides, their preparation process and use | AKZO NOBEL NV (NL) | 2002-11-19 | — | — | US | disclosed |
| EP-0950057-B1 | 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS | ABBOTT LAB (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6462194-B1 | Endothelin antagonists | ABBOTT LABORATORIES | 2002-10-08 | — | — | US | disclosed |
| US-20020142968-A1 | Prodrugs of thrombin inhibitors | ASTRAZENECA AB | 2002-10-03 | — | — | US | disclosed |
| EP-1242059-A2 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2002-09-25 | — | — | EP | disclosed |
| EP-1231212-A1 | Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders | Pfizer Products Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
| US-20020103392-A1 | CORTICOID-17,21-DICARBOXYLIC ESTERS AND CORTICOSTEROID 17-CARBOXYLIC ESTER 21-CARBONIC ESTERS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-01 | — | — | US | disclosed |
| US-20020099061-A1 | Adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-07-25 | — | — | US | disclosed |
| US-20020095035-A1 | N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase | WARSHAWSKY ALAN M (US) | 2002-07-18 | — | — | US | disclosed |
| US-6420541-B1 | MEMBRANE PROTEIN FOR USE IN TREATING PSYCHOLOGICAL, NERVOUS SYSTEM, EATING AND SEXUAL DISORDERS | ARENA PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | disclosed |
| EP-1218361-A1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6414002-B1 | ANTILIPEMIC AGENTS; ANTICANCER, ANTITUMOR AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-02 | — | — | US | disclosed |
| US-20020082254-A1 | Compounds for treating disorders where a decreased level of plasma FFA is desired | NOVO NORDISK A/S (DK) | 2002-06-27 | — | — | US | disclosed |
| EP-0733628-B9 | 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1H-indoles: 5-HT1F agonists | LILLY CO ELI (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-0776324-B1 | ENDOTHELIN ANTAGONISTS | ABBOTT LAB (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6403575-B1 | ANTI-INFLAMMATORIES | ABBOTT LABORATORIES | 2002-06-11 | — | — | US | disclosed |
| WO-2002040477-A2 | SAFRAMYCINS, ANALOGUES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2002-05-23 | — | — | WO | disclosed |
| US-20020052417-A1 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-05-02 | — | — | US | disclosed |
| WO-2002034751-A1 | HEXAHYDRO-4-OXOAZEPINO[3,2,1-HI]INDOLES | NOVARTIS AG (CH) | 2002-05-02 | — | — | WO | disclosed |
| US-6380201-B1 | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F agonists | ELI LILLY AND COMPANY | 2002-04-30 | — | — | US | disclosed |
| US-6380241-B1 | FOR THERAPY OF CORONARY ANGINA, CEREBRAL VASOSPASM, ACUTE AND CHRONIC RENAL FAILURE, GASTRIC ULCERATION, CYCLOSPORIN-INDUCED NEPHROTOXICITY, ENDOTOXIN-INDUCED TOXICITY, ASTHMA, LPL-RELATED LIPOPROTEIN DISORDERS, PROLIFERATIVE DISEASES | ABBOTT LABORATORIES | 2002-04-30 | — | — | US | disclosed |
| US-20020045777-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | F.HOFFMANN-LA ROCHE AG (CH) | 2002-04-18 | — | — | US | disclosed |
| US-6369057-B1 | VIRICIDES, IN PARTICULAR AGAINST RETROVIRUSES, HUMAN IMMUNODEFICIENCY VIRUS (HIV) | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |
| US-20020040146-A1 | Pyrrolidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2002-04-04 | — | — | US | disclosed |
| US-20020037856-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. | 2002-03-28 | — | — | US | disclosed |
| US-20020037859-A1 | 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases | AVENTISUB INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1186603-A2 | Processes for preparing endothelin antagonists | Abbott Laboratories (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2002018391-A1 | COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002017912-A1 | ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6352976-B1 | ENZYME INHIBITORS OF MATRIX METALLOPROTEINASE FOR EMPHYSEMA | AVENTIS PHARMACEUTICALS INC. | 2002-03-05 | — | — | US | disclosed |
| EP-1181266-A1 | SQUARIC ACID DERIVATIVES AS CELL ADHESION MOLECULES | Celltech R&D Limited (GB) | 2002-02-27 | — | — | EP | disclosed |
| WO-2002014267-A1 | NOVEL AMINOCYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-21 | — | — | WO | disclosed |
| US-20020019437-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-02-14 | — | — | US | disclosed |
| US-6346615-B1 | SPIROADAMANTYL DIOXETANES BEARING AN ALKOXY SUBSTITUENT, AND AN AROMATIC SUBSTITUENT ON THE DIOXETANE RING CAN BE ACTIVATED TO CHEMILUMINESCE IF THE AROMATIC SUBSTITUENT BEARS A MOIETY THAT IS CLEAVED BY AN ENZYME | TROPIX, INC. | 2002-02-12 | — | — | US | disclosed |
| WO-2002008185-A1 | PYRROLIDINE DERIVATIVES AS METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-31 | — | — | WO | disclosed |
| WO-2002000650-A2 | NOVEL COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001094301-A2 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-12-13 | — | — | WO | disclosed |
| EP-1162194-A1 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use | Aventis Pharma Deutschland GmbH (DE) | 2001-12-12 | — | — | EP | disclosed |
| US-6329550-B1 | FOR THERAPY OF EMPHYSEMA, OSTEOPOROSIS, RHEUMATOID ARTHRITIS AND NEOPLASTIC DISEASES | AVENTIS PHARMACEUTICALS INC. | 2001-12-11 | — | — | US | disclosed |
| WO-2001092264-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001087843-A1 | COMPOUNDS FOR TREATING DISORDERS WHERE A DECREASED LEVEL OF PLASMA FFA IS DESIRED | NOVO NORDISK A/S (DK) | 2001-11-22 | — | — | WO | disclosed |
| EP-1150951-A1 | 3-SUBSTITUTED PYRROLIDINES USEFUL AS INHIBITORS OF MATRIX METALLO-PROTEINASES | Aventis Pharmaceuticals Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| EP-1150975-A1 | 1-CARBOXYMETHYL-2-OXO-AZEPAN DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF MMP-12 | Aventis Pharmaceuticals Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| EP-1150976-A1 | 3-(THIO-SUBSTITUTED AMIDO)-LACTAMS USEFUL AS INHIBITORS OF MATRIX METALLOPROTEINASE | Aventis Pharmaceuticals Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| EP-1150957-A1 | N-CARBOXYMETHYL SUBSTITUTED BENZOLACTAMS AS INHIBITORS OF MATRIX METALLOPROTEINASE | Aventis Pharmaceuticals Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| EP-1147085-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | American Cyanamid Company (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1144368-A2 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1140818-A1 | AMIDOMALONAMIDES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASE | Aventis Pharmaceuticals Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140984-A1 | SELECTIVE INHIBITORS OF MMP-12 | Aventis Pharmaceuticals Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6291475-B1 | 3,7-DIAZABICYCLO(3.3.1)NONANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-09-18 | — | — | US | disclosed |
| EP-0995755-B1 | Prodrugs of Thrombin inhibitors | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | EP | disclosed |
| US-6262080-B1 | 3-(thio-substitutedamido)-lactams useful as inhibitors of matrix metalloproteinase | AVANTIS PHARMACEUTICALS INC. | 2001-07-17 | — | — | US | disclosed |
| US-6262028-B1 | CONTAINING OXY-SUBSTITUTED AMIDINOBENZYL DERIVATIVES OF DIPEPTIDES FROM CYCLOHEXYLGLYCINE AND AZETIDINE-2-CARBOXYLIC ACID; ximelagatran | ASTRAZENECA AB (SE) | 2001-07-17 | — | — | US | disclosed |
| EP-0812835-B1 | OPTICALLY ACTIVE THIAZOLIDINONE DERIVATIVES | SANKYO CO (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-6225311-B1 | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors | AMERICAN CYANAMID COMPANY | 2001-05-01 | — | — | US | disclosed |
| WO-2001021602-A1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-03-29 | — | — | WO | disclosed |
| CN-1062562-C | Corticosteroid 17-alkyl carbonate 21-[O]-carboxylic and carbonic esters, processes for their preparation, and pharmaceuticals containing these compounds | HOECHST AG (DE) | 2001-02-28 | — | — | CN | disclosed |
| EP-1028721-A4 | N,N'-BIS(SULFONYL)HYDRAZINES USEFUL AS ANTINEOPLASTIC AGENTS | UNIV YALE (US) | 2001-01-31 | — | — | EP | disclosed |
| EP-1071662-A1 | PEROXIDES, THEIR PREPARATION PROCESS AND USE | Akzo Nobel N.V. (NL) | 2001-01-31 | — | — | EP | disclosed |
| EP-1071701-A1 | NON-ENDOGENOUS, CONSTITUTIVELY ACTIVATED HUMAN SEROTONIN RECEPTORS AND SMALL MOLECULE MODULATORS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2001-01-31 | — | — | EP | disclosed |
| WO-2001003685-A2 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2001-01-18 | — | — | WO | disclosed |
| EP-0733628-B1 | 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1H-indoles: 5-HT1F agonists | LILLY CO ELI (US) | 2000-12-27 | — | — | EP | disclosed |
| US-6162927-A | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2000-12-19 | — | — | US | disclosed |
| WO-2000073260-A1 | SQUARIC ACID DERIVATIVES AS CELL ADHESION MOLECULES | CELLTECH R&D LIMITED (GB) | 2000-12-07 | — | — | WO | disclosed |
| EP-1049668-A1 | KETONE PEROXIDE DERIVATIVES, THEIR PREPARATION AND USE | Akzo Nobel N.V. (NL) | 2000-11-08 | — | — | EP | disclosed |
| EP-1047695-A1 | NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS | AstraZeneca AB (SE) | 2000-11-02 | — | — | EP | disclosed |
| EP-1047690-A1 | HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 2000-11-02 | — | — | EP | disclosed |
| US-6140509-A | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof | ARENA PHARMACEUTICALS, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-6140495-A | SPIROADAMANTYL DIOXETANES BEARING AN ALKOXY SUBSTITUENT AND AN AROMATIC SUBSTITUENT OF PHENYL OR NAPHTHYL ON THE DIOXETANE RING; REPORTER MOLECULES FOR MEASUREMENT OF ENZYMATIC ACTIVITY | TROPIX, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-6133253-A | NEURONAL CELL DEATH PREVENTORS AND ANTI-INFLAMMATORIES | ABBOTT LABORATORIES (US) | 2000-10-17 | — | — | US | disclosed |
| EP-1028721-A1 | $i(N,N')-BIS(SULFONYL)HYDRAZINES USEFUL AS ANTINEOPLASTIC AGENTS | Yale University (US) | 2000-08-23 | — | — | EP | disclosed |
| US-6107324-A | CONTROLLING SEROTONIN | ARENA PHARMACEUTICALS INC. (US) | 2000-08-22 | — | — | US | disclosed |
| WO-2000044709-A2 | ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000044723-A1 | ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS/TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000040564-A1 | N-CARBOXYMETHYL SUBSTITUTED BENZOLACTAMS AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000040552-A1 | AMIDOMALONAMIDES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000040578-A1 | 3-(THIO-SUBSTITUTED AMIDO)-LACTAMS USEFUL AS INHIBITORS OF MATRIX METALLOPROTEINASE | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000040577-A1 | 1-CARBOXYMETHYL-2-OXO-AZEPAN DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF MMP-12 | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000040600-A1 | SELECTIVE INHIBITORS OF MMP-12 | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| WO-2000040553-A1 | 3-SUBSTITUTED PYRROLIDINES USEFUL AS INHIBITORS OF MATRIX METALLO-PROTEINASES | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| EP-1003740-A2 | PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGOISTS | Abbott Laboratories (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-0944594-A4 | INHIBITORS OF THE ENZYMATIC ACTIVITY OF PSA | LILLY CO ELI (US) | 2000-05-03 | — | — | EP | disclosed |
| EP-0995755-A1 | Prodrugs of Thrombin inhibitors | Astra Aktiebolag (SE) | 2000-04-26 | — | — | EP | disclosed |
| US-6040338-A | N,n-bis(sulfonyl)hydrazines useful as antineoplastic agents | YALE UNIVERSITY (US) | 2000-03-21 | — | — | US | disclosed |
| US-6022964-A | SPIROADAMANTYL DIOXETANES WITH AN ALKOXY SUBSTITUENT AND A NAPHTHYL SUBSTITUENT ON THE DIOXETANE RING WHICH CAN BE ACTIVATED BY ENZYMATIC CLEAVAGE OF LABILE GROUP; KINETICS AND SIGNAL INTENSITY DEPENDS ON ELECTRON-ACTIVATING GROUP | TROPIX, INC. (US) | 2000-02-08 | — | — | US | disclosed |
| EP-0973936-A1 | COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC AMINOTHIOETHER ACIDS | ELI LILLY AND COMPANY (US) | 2000-01-26 | — | — | EP | disclosed |
| US-5973188-A | Acetic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 1999-10-26 | — | — | US | disclosed |
| WO-1999052864-A1 | PEROXIDES, THEIR PREPARATION PROCESS AND USE | AKZO NOBEL N.V. (NL) | 1999-10-21 | — | — | WO | disclosed |
| WO-1999052927-A1 | NON-ENDOGENOUS, CONSTITUTIVELY ACTIVATED HUMAN SEROTONIN RECEPTORS AND SMALL MOLECULE MODULATORS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 1999-10-21 | — | — | WO | disclosed |
| EP-0950057-A1 | 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS | Abbott Laboratories (US) | 1999-10-20 | — | — | EP | disclosed |
| US-5965692-A | ANTICOAGULANTS FOR TREATMENT OF THROMOBOSIS AND HYPERCOAGULABILITY IN BLOOD AND TISSUES | ASTRA AB (SE) | 1999-10-12 | — | — | US | disclosed |
| US-5962473-A | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F | ELI LILLY AND COMPANY (US) | 1999-10-05 | — | — | US | disclosed |
| US-5962474-A | ANALGESICS; HEADACHES | ELI LILLY AND COMPANY (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0944594-A1 | INHIBITORS OF THE ENZYMATIC ACTIVITY OF PSA | ELI LILLY AND COMPANY (US) | 1999-09-29 | — | — | EP | disclosed |
| US-5942387-A | Combinatorial process for preparing substituted thiophene libraries | ELI LILLY AND COMPANY (US) | 1999-08-24 | — | — | US | disclosed |
| EP-0718277-B1 | Method for producing 5-substituted-2-acylaminophenols, and 5-alkyl-2-acylaminophenol compound and N-acyl-N-(4-alkyl-phenyl)hydroxylamine compound | FUJI PHOTO FILM CO LTD (JP) | 1999-07-21 | — | — | EP | disclosed |
| US-5925658-A | PREVENTING OR TREATING ANGINA PECTORIS | SANKYO COMPANY, LIMITED (JP) | 1999-07-20 | — | — | US | disclosed |
| EP-0928291-A1 | 3-MERCAPTOACETYLAMINO-1,5-SUBSTITUTED-2-OXO-AZEPAN DERIVATIVES USEFUL AS INHIBITORS OF MATRIX METALLOPROTEINASE | HOECHST MARION ROUSSEL, INC. (US) | 1999-07-14 | — | — | EP | disclosed |
| WO-1999032442-A1 | KETONE PEROXIDE DERIVATIVES, THEIR PREPARATION AND USE | AKZO NOBEL N.V. (NL) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032480-A1 | HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999031100-A1 | NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999022726-A1 | N,N'-BIS(SULFONYL)HYDRAZINES USEFUL AS ANTINEOPLASTIC AGENTS | YALE UNIVERSITY (US) | 1999-05-14 | — | — | WO | disclosed |
| US-5891898-A | ANTIULCER AGENT | SANKYO COMPANY, LIMITED (JP) | 1999-04-06 | — | — | US | disclosed |
| US-5892091-A | PHOSPHOROUS CATALYSTS AND HALOGEN ATOMS | UBE INDUSTRIES, LTD. (JP) | 1999-04-06 | — | — | US | disclosed |
| WO-1999006397-A2 | PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1999-02-11 | — | — | WO | disclosed |
| EP-0885215-A1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5851771-A | Chemiluminescent 1,2-dioxetanes | TROPIX, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| WO-1998057173-A1 | COMBINATORIAL PROCESS FOR PREPARING SUBSTITUTED PHENYLALANINE LIBRARIES | ELI LILLY AND COMPANY (US) | 1998-12-17 | — | — | WO | disclosed |
| US-5843983-A | Diphenylethane compounds containing a saturated heterocyclic group, their preparation, and their therapeutic use | SANKYO COMPANY, LIMITED (JP) | 1998-12-01 | — | — | US | disclosed |
| US-5840919-A | SPIROADAMANTYL 1,2-DIOXETANES CHARACTERIZED BY SUBSTITUENT ON AROMATIC RING IN ADDITION TO META-SUBSTITUTED ENZYME-LABILE GROUP | TROPIX, INC. (US) | 1998-11-24 | — | — | US | disclosed |
| WO-1998046786-A1 | COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC AMINOTHIOETHER ACIDS | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| EP-0869966-A1 | PRODRUGS OF THROMBIN INHIBITORS | Astra Aktiebolag (SE) | 1998-10-14 | — | — | EP | disclosed |
| WO-1998025895-A1 | INHIBITORS OF THE ENZYMATIC ACTIVITY OF PSA | ELI LILLY AND COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
| WO-1998025920-A1 | 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS | ABBOTT LABORATORIES (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5767144-A | Endothelin antagonists | ABBOTT LABORATORIES (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0832650-A2 | Use of serotonin 5-HT1F agonists for the prevention of migraine | ELI LILLY AND COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5733882-A | Retroviral protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1998-03-31 | — | — | US | disclosed |
| WO-1998012211-A1 | 3-MERCAPTOACETYLAMINO-1,5-SUBSTITUTED-2-OXO-AZEPAN DERIVATIVES USEFUL AS INHIBITORS OF MATRIX METALLOPROTEINASE | HOECHST MARION ROUSSEL, INC. (US) | 1998-03-26 | — | — | WO | disclosed |
| WO-1998011895-A1 | A METHOD FOR THE PREVENTION OF MIGRAINE | ELI LILLY AND COMPANY (US) | 1998-03-26 | — | — | WO | disclosed |
| US-5731434-A | CARDIOVASCULAR DISORDERS | ABBOTT LABORATORIES (US) | 1998-03-24 | — | — | US | disclosed |
| US-5726185-A | BINDING OF ADHESIVE PROTEINS TO BLOOD PLATELET AGGREGATION AND CELL TO CELL ADHESION | HOFFMANN-LA ROCHE INC. (US) | 1998-03-10 | — | — | US | disclosed |
| WO-1998008813-A1 | COMBINATORIAL PROCESS FOR PREPARING SUBSTITUTED PYRROLIDINE LIBRARIES | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| EP-0826658-A1 | Catalyst for decarbonylation reaction | UBE INDUSTRIES, LTD. (JP) | 1998-03-04 | — | — | EP | disclosed |
| EP-0824917-A2 | Use of a serotonin 5-HTlf agonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis | ELI LILLY AND COMPANY (US) | 1998-02-25 | — | — | EP | disclosed |
| EP-0825164-A2 | Scavenger assisted combinatorial process for preparing libraries of amides, carbamates and sulfonamides | ELI LILLY AND COMPANY (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1998006402-A1 | TREATMENT OF THE COMMON COLD OR ALLERGIC RHINITIS | ELI LILLY AND COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
| US-5708008-A | TREATMENT OF MIGRAINE | ELI LILLY AND COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| EP-0812835-A1 | OPTICALLY ACTIVE THIAZOLIDINONE DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1997-12-17 | — | — | EP | disclosed |
| EP-0799230-A1 | THIENOXAZINONE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1997-10-08 | — | — | EP | disclosed |
| WO-1997030045-A1 | NOVEL BENZO-1,3-DIOXOLYL- AND BENZOFURANYL SUBSTITUTED PYRROLIDINE DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1997-08-21 | — | — | WO | disclosed |
| EP-0790235-A1 | Diaryl alkane derivatives containing an alicyclic group, their preparation and their therapeutic and prophylactic uses | SANKYO COMPANY LIMITED (JP) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997023499-A1 | PRODRUGS OF THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1997-07-03 | — | — | WO | disclosed |
| US-5622971-A | PIPERIDINE DERIVATIVES; HYPOTENSIVE AGENTS | ABBOTT LABORATORIES (US) | 1997-04-22 | — | — | US | disclosed |
| EP-0669923-B1 | RAPAMYCIN CARBONATE ESTERS AS IMMUNOSUPPRESSANT AGENTS | AMERICAN HOME PROD (US) | 1997-04-16 | — | — | EP | disclosed |
| US-5608093-A | ANTIINFLAMMATORY AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-03-04 | — | — | US | disclosed |
| US-RE35462-E | Silylated benzoic acid derivatives | CONSORTIUM FUR ELEKOCHEMISCHE IND. GMBH (DE) | 1997-02-25 | — | — | US | disclosed |
| WO-1997000244-A1 | PROCESS FOR PARALLEL SYNTHESIS OF A NON-PEPTIDE LIBRARY | ELI LILLY AND COMPANY (US) | 1997-01-03 | — | — | WO | disclosed |
| WO-1996029075-A1 | 5-SUBSTITUTED-3-(1,2,3,6-TETRAHYDROPYRIDIN-4-YL)- AND 3-(PIPERIDIN-4-YL)-1H-INDOLES: NEW 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1996-09-26 | — | — | WO | disclosed |
| EP-0733628-A1 | 5-Substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
| EP-0509769-B1 | Heterocyclic amides having HLE inhibiting activity | ZENECA LTD (GB) | 1996-09-11 | — | — | EP | disclosed |
| US-5538847-A | Chemiluminescent 1,2-dioxetanes | TROPIX, INC. (US) | 1996-07-23 | — | — | US | disclosed |
| WO-1996019482-A1 | THIENOXAZINONE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1996-06-27 | — | — | WO | disclosed |
| EP-0718277-A1 | Method for producing 5-substituted-2-acylaminophenols, and 5-alkyl-2-acylaminophenol compound and N-acyl-N-(4-alkyl-phenyl)hydroxylamine compound | FUJI PHOTO FILM CO., LTD. (JP) | 1996-06-26 | — | — | EP | disclosed |
| US-5521179-A | Heterocyclic amides | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| WO-1996006095-A1 | ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1996-02-29 | — | — | WO | disclosed |
| EP-0669923-A1 | RAPAMYCIN CARBONATE ESTERS AS IMMUNOSUPPRESSANT AGENTS. | AMERICAN HOME PROD (US) | 1995-09-06 | — | — | EP | disclosed |
| EP-0524419-B1 | Heat-sensitive recording materials and phenol compounds | MITSUI TOATSU CHEMICALS (JP) | 1995-09-06 | — | — | EP | disclosed |
| EP-0443474-B1 | 1-Phenoxycarbonyl-2-pyrrolidinone derivatives and nootropic agents | NISSHIN FLOUR MILLING CO (JP) | 1995-08-16 | — | — | EP | disclosed |
| CN-1105368-A | Corticosteroid 17-alkyl carbonate 21-[O]-carboxylic and carbonic esters, processes for their preparation, and pharmaceuticals containing these compounds | HOECHST AG (DE) | 1995-07-19 | — | — | CN | disclosed |
| EP-0602069-A4 | RETROVIRAL PROTEASE INHIBITORS. | SMITHKLINE BEECHAM CORP (US) | 1995-05-03 | — | — | EP | disclosed |
| EP-0649417-A1 | IMPROVED CHEMILUMINESCENT 1,2-DIOXETANES | TROPIX, INC. (US) | 1995-04-26 | — | — | EP | disclosed |
| EP-0649417-A4 | IMPROVED CHEMILUMINESCENT 1,2-DIOXETANES. | TROPIX INC (US) | 1995-02-27 | — | — | EP | disclosed |
| US-5391806-A | A storage stable chromogens as color-developing agent or stabilizers | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-02-21 | — | — | US | disclosed |
| WO-1994026726-A1 | IMPROVED CHEMILUMINESCENT 1,2-DIOXETANES | TROPIX, INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| JP-H06298926-A | PRODUCTION OF AROMATIC POLYCARBONATE | MITSUI TOATSU CHEM INC | 1994-10-25 | — | — | JP | disclosed |
| US-5356914-A | Cognition activators | BEECHAM GROUP P.L.C. (GB) | 1994-10-18 | — | — | US | disclosed |
| EP-0602069-A1 | RETROVIRAL PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-06-22 | — | — | EP | disclosed |
| WO-1994011380-A1 | RAPAMYCIN CARBONATE ESTERS AS IMMUNOSUPPRESSANT AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-05-26 | — | — | WO | disclosed |
| EP-0588317-A1 | Uridine derivative and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1994-03-23 | — | — | EP | disclosed |
| US-5277838-A | Silylated benzoic acid derivatives | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1994-01-11 | — | — | US | disclosed |
| US-5270281-A | Chromogenic compound | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1993-12-14 | — | — | US | disclosed |
| US-5260300-A | Useful in treatment of transplant rejection; administering | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0552213-A1 | 1,2,5,6-TETRAHYDROPYRIDINE OXIME DERIVATIVES | BEECHAM GROUP PLC (GB) | 1993-07-28 | — | — | EP | disclosed |
| WO-1993002057-A1 | RETROVIRAL PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-02-04 | — | — | WO | disclosed |
| EP-0524419-A1 | Heat-sensitive recording materials and phenol compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-01-27 | — | — | EP | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
| US-5141954-A | Fungicides | MERCK & CO., INC. (US) | 1992-08-25 | — | — | US | disclosed |
| US-5140041-A | Cognition activators, for treatment of Alzheimer's disease | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1992-08-18 | — | — | US | disclosed |
| WO-1992006959-A1 | 1,2,5,6-TETRAHYDROPYRIDINE OXIME DERIVATIVES | BEECHAM GROUP PLC (GB) | 1992-04-30 | — | — | WO | disclosed |
| US-5106530-A | Liquid crystals | Consortium Fur Elektrochemische Ind. (DE) | 1992-04-21 | — | — | US | disclosed |
| US-5091541-A | Useful as alzheimer's disease | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1992-02-25 | — | — | US | disclosed |
| EP-0443474-A2 | 1-Phenoxycarbonyl-2-pyrrolidinone derivatives and nootropic agents | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1991-08-28 | — | — | EP | disclosed |
| EP-0440145-A1 | Hexahydropyrrolo[2,3-b]indole carbamates,-ureas,-amides and related compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-08-07 | — | — | EP | disclosed |
| US-4983616-A | Analgesics, cognition activators | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1991-01-08 | — | — | US | disclosed |
| US-4812590-A | Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma | MERCK & CO., INC. (US) | 1989-03-14 | — | — | US | disclosed |
| EP-0296811-A2 | Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma | MERCK & CO. INC. (US) | 1988-12-28 | — | — | EP | disclosed |
| US-4723029-A | Organic acid-substituted guanidine anthelmintics | SCHERING CORPORATION (US) | 1988-02-02 | — | — | US | disclosed |
| US-4618364-A | 3-(2-tetrahydropyranyl)-1,2,3,4,5,6,7-hexahydro-1-p-tolyloxycarbonyl-5H-cyclopentapyrimidine-2,4-dione and herbicidal compositions and methods using it | ROUSSEL UCLAF (FR) | 1986-10-21 | — | — | US | disclosed |
| US-4591583-A | TREATING VIRAL INFECTIONS | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1986-05-27 | — | — | US | disclosed |
| EP-0156889-A1 | PHENYLGUANIDINES | SCHERING CORPORATION (US) | 1985-10-09 | — | — | EP | disclosed |
| US-4536400-A | VIRICIDES | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1985-08-20 | — | — | US | disclosed |
| EP-0147537-A1 | Phenylguanidines | SCHERING CORPORATION (US) | 1985-07-10 | — | — | EP | disclosed |
| WO-1985001283-A1 | PHENYLGUANIDINES | SCHERING CORP. (US) | 1985-03-28 | — | — | WO | disclosed |
| US-4477563-A | DEVELOPMENT INHIBITION RELEASING COUPLERS | FUJI PHOTO FILM CO., LTD. (JP) | 1984-10-16 | — | — | US | disclosed |
| US-4386081-A | VIRICIDE | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1983-05-31 | — | — | US | disclosed |
| US-4376731-A | 2-NITRILES THEREOF | BOEHRINGER MANNHEIM GMBH (DE) | 1983-03-15 | — | — | US | disclosed |
| US-4372894-A | VIRICIDES | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1983-02-08 | — | — | US | disclosed |
| EP-0003007-B1 | ALIPHATIC DERIVATIVES OF PHOSPHONOFORMIC ACID, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR COMBATING VIRUS INFECTIONS | Astra Läkemedel Aktiebolag (SE) | 1982-04-07 | — | — | EP | disclosed |
| EP-0003275-B1 | AROMATIC DERIVATIVES OF PHOSPHONOFORMIC ACID, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE FOR COMBATING VIRUS INFECTIONS | Astra Läkemedel Aktiebolag (SE) | 1981-09-02 | — | — | EP | disclosed |
| EP-0003275-A1 | Aromatic derivatives of phosphonoformic acid, processes for their preparation, pharmaceutical compositions containing them and their use for combating virus infections | Astra Läkemedel Aktiebolag (SE) | 1979-08-08 | — | — | EP | disclosed |
| EP-0003007-A2 | Aliphatic derivatives of phosphonoformic acid, pharmaceutical compositions and methods for combating virus infections | Astra Läkemedel Aktiebolag (SE) | 1979-07-11 | — | — | EP | disclosed |
| US-3948967-A | HERBICIDE, FUNGICIDE | VELSICOL CHEMICAL CORPORATION (US) | 1976-04-06 | — | — | US | disclosed |
| US-3948967-A | HERBICIDE, FUNGICIDE | VELSICOL CHEMICAL CORPORATION (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008849-A1 | Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | CES2 2358/4885CES1 213/4885CA1 53/4885 |
| US-20110144081-A1 | PYRROLIDINE DERIVATIVES | TACR1, OPRL1, SLC6A3 | CES2 2414/4885CES1 3424/4885CA1 4803/4885 |
| US-11780844-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | CES2 205/4885CES1 974/4885CA1 1982/4885 |
| US-20110251389-A1 | Process For Making N-(Diphenylmethyl)piperazines | CYP51A1, CYP3A5, CYP4Z1 | CES2 645/4885CES1 361/4885CA1 3156/4885 |
| US-20110130387-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | CES2 3967/4885CES1 1762/4885CA1 4754/4885 |
| US-20080064688-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | CES2 2777/4885CES1 3797/4885CA1 1588/4885 |
| US-20230391731-A1 | PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF | GRPR, SLC2A8, HPGDS | CES2 103/4885CES1 302/4885CA1 2173/4885 |
| US-20100120793-A1 | Pyrrolidines | PTGER2, PTGDR2, PTGES2 | CES2 2304/4885CES1 3129/4885CA1 3390/4885 |
| US-20090227574-A2 | Administration of Carboline Derivatives Useful in the Treatment of Cancer and Other Diseases | VEGFA, FLT4, FLT1 | CES2 2810/4885CES1 2394/4885CA1 2949/4885 |
| US-20240150359-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | CES2 205/4885CES1 974/4885CA1 1982/4885 |
| US-20230279015-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | CES2 205/4885CES1 974/4885CA1 1982/4885 |
| US-20110160190-A1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | VEGFA, FLT4, PGF | CES2 3248/4885CES1 3301/4885CA1 2984/4885 |
| US-20050288343-A1 | Process of preparing substituted carbamates and intermediates thereof | CPS1, LIPA, LCAT | CES2 42/4885CES1 9/4885CA1 971/4885 |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | CES2 91/4885CES1 22/4885CA1 4261/4885 |
| US-20030092697-A1 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, GLP1R | CES2 67/4885CES1 13/4885CA1 3880/4885 |
| US-10035800-B2 | Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors | BRD1, BRD3, BRD4 | CES2 481/4885CES1 392/4885CA1 1437/4885 |
| US-20090312547-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN CALCIUM FIELD OF THE INVENTION | CACNA1C, CACNG5, CACNA1A | CES2 4035/4885CES1 1395/4885CA1 793/4885 |
| US-20040142857-A1 | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | TYMP, GDA, GCG | CES2 1602/4885CES1 808/4885CA1 2735/4885 |
| US-20040147555-A1 | Benzamidine derivatives | F9, F7, F2 | CES2 1013/4885CES1 267/4885CA1 2734/4885 |
| US-20180298003-A1 | TETRACYCLIC BROMODOMAIN INHIBITORS | BRD3, BRD4, BRD1 | CES2 1197/4885CES1 999/4885CA1 1983/4885 |
| US-20120258959-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR65, GPR27 | CES2 4471/4885CES1 1430/4885CA1 4859/4885 |
| US-20100168181-A1 | BENZIMIDAZOLE AMIDO DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | CYP3A5, TMBIM6, FANCI | CES2 1644/4885CES1 341/4885CA1 4501/4885 |
| US-20090105230-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | CES2 2777/4885CES1 3797/4885CA1 1588/4885 |
| US-20040033988-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | CES2 2358/4885CES1 213/4885CA1 53/4885 |
| US-20040204419-A1 | Saframycins, analogues and uses thereof | MYC, MAN1B1, MRPS18A | CES2 2936/4885CES1 2306/4885CA1 4337/4885 |
| US-20100048550-A1 | SELECTIVE TR-BETA 1 AGONIST | THRB, THRA, TSHR | CES2 3978/4885CES1 1058/4885CA1 4069/4885 |
| US-20070299068-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | CES2 212/4885CES1 227/4885CA1 1456/4885 |
| US-20040063762-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | GLP1R, ZYX, SLC5A2 | CES2 31/4885CES1 25/4885CA1 3172/4885 |
| US-20100216772-A1 | Novel Phenantridine Analogues and Uses Thereof | P2RX4, P2RX5, CLIC4 | CES2 546/4885CES1 2893/4885CA1 3965/4885 |
| US-20090227583-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2B | CES2 1831/4885CES1 4071/4885CA1 4171/4885 |
| US-20100016254-A1 | GEMCITABINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TYMP, GDA, GCG | CES2 1608/4885CES1 754/4885CA1 2700/4885 |
| US-20030069275-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, PNLIP | CES2 226/4885CES1 23/4885CA1 2579/4885 |
| US-20080113968-A1 | Substituted piperazines and diazepanes | HRH3, HRH4, HRH1 | CES2 2128/4885CES1 2221/4885CA1 2892/4885 |
| US-20090075986-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | CES2 2777/4885CES1 3797/4885CA1 1588/4885 |
| US-20140163079-A1 | DIPHOSPHATE MIMETICS AND USES THEREOF | PLK1, OGA, MAPKAPK2 | CES2 4793/4885CES1 3945/4885CA1 3966/4885 |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | CES2 1272/4885CES1 3678/4885CA1 4653/4885 |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | CES2 1172/4885CES1 568/4885CA1 3155/4885 |
| US-20110136783-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR6, GPR139 | CES2 2234/4885CES1 878/4885CA1 4243/4885 |
| US-20040072690-A1 | Novel propionic acid derivatives | PNLIP, LIPC, GPR119 | CES2 1226/4885CES1 15/4885CA1 2835/4885 |
| US-12180217-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, OAT | CES2 205/4885CES1 974/4885CA1 1982/4885 |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | CES2 3967/4885CES1 1762/4885CA1 4754/4885 |
| US-20030119749-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | CYP51A1, MCL1, ERG28 | CES2 3607/4885CES1 3207/4885CA1 3705/4885 |
| US-20070275956-A1 | Novel Heterocyclic Compounds | CYP46A1, DHCR7, NPC1L1 | CES2 378/4885CES1 42/4885CA1 3926/4885 |
| US-20020177591-A1 | Pharmaceutical compositions for the treatment of CNS and other discorders | CHRNA7, CHRNA5, CHRNA10 | CES2 342/4885CES1 880/4885CA1 2897/4885 |
| US-20070112008-A1 | Saframycins, analogues and uses thereof | MYC, MAN1B1, MRPS18A | CES2 3073/4885CES1 2706/4885CA1 4449/4885 |
| US-20090076102-A1 | DEUTERIUM-ENRICHED MURAGLITAZAR | GIPR, GLP1R, DPP4 | CES2 3735/4885CES1 1946/4885CA1 1408/4885 |
| US-20080015238-A1 | CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | GPR119, PC, ACADM | CES2 266/4885CES1 78/4885CA1 4218/4885 |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | CES2 3609/4885CES1 2453/4885CA1 4778/4885 |
| US-20230279014-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, OAT | CES2 205/4885CES1 974/4885CA1 1982/4885 |
| US-20030212049-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, TASP1 | CES2 2358/4885CES1 213/4885CA1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.